Cargando…

Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch

Kappa opioid receptor (KOR) agonists have been promising therapeutic candidates, owing to their potential for relieving pain and treating intractable pruritus. Although lacking morphine-like central nervous system (CNS) effects, KOR agonists do elicit sedation, dysphoria and diuresis which seriously...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xin, Gou, Xiaoli, Yu, Xiaojuan, Bai, Dongdong, Tan, Bowei, Cao, Pingfeng, Qian, Meilin, Zheng, Xiaoxiao, Wang, Hairong, Tang, Pingming, Zhang, Chen, Ye, Fei, Ni, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635029/
https://www.ncbi.nlm.nih.gov/pubmed/34867403
http://dx.doi.org/10.3389/fphar.2021.773204
_version_ 1784608221998088192
author Wang, Xin
Gou, Xiaoli
Yu, Xiaojuan
Bai, Dongdong
Tan, Bowei
Cao, Pingfeng
Qian, Meilin
Zheng, Xiaoxiao
Wang, Hairong
Tang, Pingming
Zhang, Chen
Ye, Fei
Ni, Jia
author_facet Wang, Xin
Gou, Xiaoli
Yu, Xiaojuan
Bai, Dongdong
Tan, Bowei
Cao, Pingfeng
Qian, Meilin
Zheng, Xiaoxiao
Wang, Hairong
Tang, Pingming
Zhang, Chen
Ye, Fei
Ni, Jia
author_sort Wang, Xin
collection PubMed
description Kappa opioid receptor (KOR) agonists have been promising therapeutic candidates, owing to their potential for relieving pain and treating intractable pruritus. Although lacking morphine-like central nervous system (CNS) effects, KOR agonists do elicit sedation, dysphoria and diuresis which seriously impede their development. Peripherally-restricted KOR agonists have a poor ability to penetrate into the CNS system, so that CNS-related adverse effects can be ameliorated or even abolished. However, the only approved peripherally-restricted KOR agonist CR845 remains some frequent CNS adverse events. In the present study, we aim to address pharmacological profiles of HSK21542, with an expectation to provide a safe and effective alternative for patients who are suffering from pain and pruritus. The in vitro experimental results showed that HSK21542 was a selective and potent KOR agonist with higher potency than CR845, and had a brain/plasma concentration ratio of 0.001, indicating its peripheral selectivity. In animal models of pain, HSK21542 significantly inhibited acetic acid-, hindpaw incision- or chronic constriction injury-induced pain-related behaviors, and the efficacy was comparable to CR845 at 15 min post-dosing. HSK21542 had a long-lasting analgesic potency with a median effective dose of 1.48 mg/kg at 24 h post-drug in writhing test. Meanwhile, the antinociceptive activity of HSK21542 was effectively reversed by a KOR antagonist nor-binaltorphimine. In addition, HSK21542 had powerful antipruritic activities in compound 48/80-induced itch model. On the other hand, HSK21542 had a weak ability to produce central antinociceptive effects in a hot-plate test and fewer effects on the locomotor activity of mice. HSK21542 didn’t affect the respiratory rate of mice. Therefore, HSK21542 might be a safe and effective KOR agonist and promising candidate for treating pain and pruritus.
format Online
Article
Text
id pubmed-8635029
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86350292021-12-02 Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch Wang, Xin Gou, Xiaoli Yu, Xiaojuan Bai, Dongdong Tan, Bowei Cao, Pingfeng Qian, Meilin Zheng, Xiaoxiao Wang, Hairong Tang, Pingming Zhang, Chen Ye, Fei Ni, Jia Front Pharmacol Pharmacology Kappa opioid receptor (KOR) agonists have been promising therapeutic candidates, owing to their potential for relieving pain and treating intractable pruritus. Although lacking morphine-like central nervous system (CNS) effects, KOR agonists do elicit sedation, dysphoria and diuresis which seriously impede their development. Peripherally-restricted KOR agonists have a poor ability to penetrate into the CNS system, so that CNS-related adverse effects can be ameliorated or even abolished. However, the only approved peripherally-restricted KOR agonist CR845 remains some frequent CNS adverse events. In the present study, we aim to address pharmacological profiles of HSK21542, with an expectation to provide a safe and effective alternative for patients who are suffering from pain and pruritus. The in vitro experimental results showed that HSK21542 was a selective and potent KOR agonist with higher potency than CR845, and had a brain/plasma concentration ratio of 0.001, indicating its peripheral selectivity. In animal models of pain, HSK21542 significantly inhibited acetic acid-, hindpaw incision- or chronic constriction injury-induced pain-related behaviors, and the efficacy was comparable to CR845 at 15 min post-dosing. HSK21542 had a long-lasting analgesic potency with a median effective dose of 1.48 mg/kg at 24 h post-drug in writhing test. Meanwhile, the antinociceptive activity of HSK21542 was effectively reversed by a KOR antagonist nor-binaltorphimine. In addition, HSK21542 had powerful antipruritic activities in compound 48/80-induced itch model. On the other hand, HSK21542 had a weak ability to produce central antinociceptive effects in a hot-plate test and fewer effects on the locomotor activity of mice. HSK21542 didn’t affect the respiratory rate of mice. Therefore, HSK21542 might be a safe and effective KOR agonist and promising candidate for treating pain and pruritus. Frontiers Media S.A. 2021-11-16 /pmc/articles/PMC8635029/ /pubmed/34867403 http://dx.doi.org/10.3389/fphar.2021.773204 Text en Copyright © 2021 Wang, Gou, Yu, Bai, Tan, Cao, Qian, Zheng, Wang, Tang, Zhang, Ye and Ni. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wang, Xin
Gou, Xiaoli
Yu, Xiaojuan
Bai, Dongdong
Tan, Bowei
Cao, Pingfeng
Qian, Meilin
Zheng, Xiaoxiao
Wang, Hairong
Tang, Pingming
Zhang, Chen
Ye, Fei
Ni, Jia
Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch
title Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch
title_full Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch
title_fullStr Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch
title_full_unstemmed Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch
title_short Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch
title_sort antinociceptive and antipruritic effects of hsk21542, a peripherally-restricted kappa opioid receptor agonist, in animal models of pain and itch
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635029/
https://www.ncbi.nlm.nih.gov/pubmed/34867403
http://dx.doi.org/10.3389/fphar.2021.773204
work_keys_str_mv AT wangxin antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch
AT gouxiaoli antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch
AT yuxiaojuan antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch
AT baidongdong antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch
AT tanbowei antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch
AT caopingfeng antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch
AT qianmeilin antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch
AT zhengxiaoxiao antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch
AT wanghairong antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch
AT tangpingming antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch
AT zhangchen antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch
AT yefei antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch
AT nijia antinociceptiveandantipruriticeffectsofhsk21542aperipherallyrestrictedkappaopioidreceptoragonistinanimalmodelsofpainanditch